Literature DB >> 31552433

Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.

Sun Moon Kim1, Song-Yi Choi2, Seon Young Kim3, Jinhyun Kim4.   

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA) may target proteinase 3 (PR3) or myeloperoxidase (MPO). Although a few patients with vasculitis have both MPO- and PR3-ANCA, the details of their clinical characteristics are not known. The objective of this study was to analyze the characteristics of patients with dual MPO- and PR3-ANCA-positive vasculitis. The medical records of patients with ANCA and vasculitis confirmed by biopsy were reviewed. The age at diagnosis, sex, and data on organ involvement of the kidney, lung, upper airways, skin, nervous system, and gastrointestinal tract were collected. Clinical variables were analyzed according to ANCA specificity. Of 85 patients with ANCA and vasculitis included in this study, 67 (78.8%) had MPO-ANCA, 10 (11.8%) had PR3-ANCA, and 8 (9.4%) had both MPO- and PR3-ANCA. Patients with MPO- PR3 + ANCA-associated vasculitis (AAV) were younger at diagnosis (median, 54.4 years; p < 0.05) than patients with MPO + PR3- AAV (67.0 years) or dual-ANCA AAV (MPO + PR3 + , 68.5 years). The initial glomerular filtration rate in patients with MPO + PR3- AAV (22.0 ml/min) was significantly lower than that in patients with MPO- PR3 + AAV (108.6 ml/min, p < 0.05), but was not different from that in dual-ANCA AAV patients (16.5 ml/min). Upper airway involvement also differed with ANCA type (MPO+ PR3- , 35.8% vs. MPO- PR3 + , 70.0% vs. MPO + PR3+ , 75.0%, p < 0.05). The involvement of other organs did not differ according to ANCA type. Age at diagnosis, kidney involvement, and upper airway involvement were associated with ANCA type. Patients with dual-ANCA-positive vasculitis had considerably more kidney dysfunction than patients with MPO- PR3+ AAV. They also had more upper airway involvement than patients with MPO+ PR3- AAV.

Entities:  

Keywords:  Anti-neutrophil cytoplasmic antibody-associated vasculitis; Antibodies, antineutrophil cytoplasmic; Granulomatosis with polyangiitis; Microscopic polyangiitis; Systemic vasculitis

Mesh:

Substances:

Year:  2019        PMID: 31552433     DOI: 10.1007/s00296-019-04447-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  41 in total

1.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

2.  Dual ANCA positivity in subacute bacterial endocarditis.

Authors:  Alexandra M Tiliakos; Nicholas A Tiliakos
Journal:  J Clin Rheumatol       Date:  2008-02       Impact factor: 3.517

3.  Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum.

Authors:  Alfred Mahr; Ulrich Specks; David Jayne
Journal:  Rheumatology (Oxford)       Date:  2019-10-01       Impact factor: 7.580

4.  Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan.

Authors:  Nobuyuki Ono; Hiroaki Niiro; Akira Ueda; Takuya Sawabe; Hiroaki Nishizaka; Isao Furugo; Seiji Yoshizawa; Shigeru Yoshizawa; Hiroshi Tsukamoto; Chikako Kiyohara; Yoshifumi Tada; Takahiko Horiuchi
Journal:  Rheumatol Int       Date:  2014-08-17       Impact factor: 2.631

5.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

7.  Dual positivity for cytoplasmic and perinuclear anti-neutrophil antibodies in a patient with Henoch-Schönlein purpura.

Authors:  I Ferraz-Amaro; M J Herrero; A Jurado; F Díaz-González
Journal:  Clin Exp Rheumatol       Date:  2004 Mar-Apr       Impact factor: 4.473

8.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Authors:  C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

9.  Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies.

Authors:  C Franssen; R Gans; C Kallenberg; C Hageluken; S Hoorntje
Journal:  J Intern Med       Date:  1998-09       Impact factor: 8.989

10.  Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis.

Authors:  Holger Brockmann; Andreas Schwarting; Jörg Kriegsmann; Peter Petrow; Andreas Gaumann; Klaus-Michael Müller; Peter Robert Galle; Werner Mayet
Journal:  Arthritis Res       Date:  2002-03-27
View more
  4 in total

1.  Rare Case of Renal Limited Dual Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Double Trouble!

Authors:  Elenjickal Elias John; Sanjeet Roy; Selvin Sundar Raj Mani; Jeethu Joseph Eapen; Utkarash Mishra; Santosh Varughese
Journal:  Eur J Case Rep Intern Med       Date:  2022-05-10

Review 2.  Classification of ANCA-associated vasculitis: differences based on ANCA specificity and clinicopathologic phenotype.

Authors:  Maricruz Domínguez-Quintana; Marco A Alba; Andrea Hinojosa-Azaola
Journal:  Rheumatol Int       Date:  2021-08-12       Impact factor: 2.631

Review 3.  ANCA Status or Clinical Phenotype - What Counts More?

Authors:  Martin Windpessl; Erica L Bettac; Philipp Gauckler; Jae Il Shin; Duvuru Geetha; Andreas Kronbichler
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

4.  Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: Our single-center, tertiary care experience.

Authors:  Aysun Toraman; Özgül Soysal Gündüz
Journal:  Arch Rheumatol       Date:  2021-05-11       Impact factor: 1.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.